Emerging therapies for chronic kidney disease: what is their role?
Eswari Vilayur
&
David C. H. Harris
p375 | doi:10.1038/nrneph.2009.76
The prevalence of chronic kidney disease (CKD) is increasing worldwide. The best therapies currently available aim to control blood pressure and maximize renin–angiotensin–aldosterone system blockade but are only partially effective in humans. A number of emerging therapies have shown benefit in animal models of CKD, and some have been tested to a limited extent in humans. This Review examines these emerging pharmacological strategies in the context of diabetic nephropathy, diabetic and nondiabetic CKD and autosomal dominant polycystic kidney disease.
Sexual dimorphism in the aging kidney: differences in the nitric oxide system
Chris Baylis
p384 | doi:10.1038/nrneph.2009.90
Glomerular filtration rate usually decreases with advancing age as a result of structural and functional changes in the aging kidney, but women are substantially protected against the age-dependent decline in renal function. This sexual dimorphism is the product of differences in chromosomes, perinatal programming and gonadal hormones (sex steroids) that create sexual phenotype. In this Review, Chris Baylis focuses on the role of the sex steroids, with a particular emphasis on the effects of sex and age on the nitric oxide system.
Integrating albuminuria and GFR in the assessment of diabetic nephropathy
George Jerums,
Sianna Panagiotopoulos,
Erosha Premaratne
&
Richard J. MacIsaac
p397 | doi:10.1038/nrneph.2009.91
The evaluation of diabetic nephropathy from both research and clinical viewpoints depends on the assessment of two continuous variables, albumin excretion rate (AER) and glomerular filtration rate (GFR). Although increases in AER generally precede a decline in GFR, some patients follow a non-albuminuric pathway to renal impairment. In this Review, George Jerums and colleagues explain why serial assessments of both AER and GFR should be performed at an early stage in patients being evaluated for diabetic nephropathy.

Circadian sleep–wake rhythm disturbances in end-stage renal disease
Birgit C. P. Koch,
J. Elsbeth Nagtegaal,
Gerard A. Kerkhof
&
Piet M. ter Wee
p407 | doi:10.1038/nrneph.2009.88
Sleep disturbances are much more prevalent in the dialysis population than in the general population, and have a major effect on the vitality and general health of these patients. In this Review, Koch and colleagues discuss circadian sleep–wake rhythm disturbances in individuals with end-stage renal disease. The possible external and internal influences on sleep–wake rhythmicity in such patients—such as the effect of dialysis, medications, melatonin and biochemical parameters—are presented, and possible approaches for strengthening the synchronization of the circadian sleep–wake rhythm are explored.